Sanofi-Aventis weight-loss drug may trigger suicidal behavior: FDA
The FDA said Monday that Sanofi-Aventis’ weight-loss drug Acomplia (rimonabant) may trigger suicidal behavior and other psychological side effects in some patients.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.